Overview

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

Status:
Terminated
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
Phase:
Phase 2
Details
Lead Sponsor:
Achillion Pharmaceuticals
Alexion Pharmaceuticals
Collaborator:
Achillion, a wholly owned subsidiary of Alexion
Treatments:
Dexelvucitabine
Lamivudine